Delphine Charvin

Biography

  Delphine defended her PhD in Neurosciences in 2005 in Paris. Then she pursued postdoctoral studies at EPFL for two years, in the laboratory of Pr Patrick Aebischer. In 2008, Delphine joined Addex Pharmaceuticals as Laboratory Head in in vitro pharmacology, being responsible for all the in vitro pharmacology experiments needed to characterize allosteric modulators (PAM, NAM and SAM) of mGluRs and other GPCR. Delphine was named Biology Project Leader for two of the main CNS drug discovery projects of Addex, including the development of mGluR4 PAMs for the treatment of Parkinson’s disease, a project partnered with Merck & Co. In 2010, Delphine joined Merck-Serono as Senior Scientist and Project Leader, managing the Geneva Parkinson’s disease in vitro laboratory. She was actively involved in drug discovery projects. She also proposed and initiated a project to discover and develop mGluR3 PAMs as a treatment of Parkinson’s disease and other neurodegenerative disorders.  

Research Interest